Clarityn-D 24Hour Extended Release Adverse Reactions

In clinical studies, the most frequently reported adverse events associated with Clarityn-D 24 Hour Extended Release were severe headache and dry mouth. Less commonly reported events were somnolence and insomnia, visual disturbance, nausea, vomiting, seizure, which were reported also at a comparable rate with placebo and other new generation antihistamine controls.
Rarely reported events in decreasing order of frequency include dizziness, fatigue, anorexia, nervousness, nausea, epistaxis, rhinitis, lacrimal gland disorder, asthenia, hyperkinesia, constipation, dyspepsia, palpitation, tachycardia, thirst, agitation, irritability, coughing, dyspnea, nasal irritation and pharyngitis.
With the exception of headache, which was occasionally severe, most of the adverse events associated with Clarityn-D 24Hour Extended Release were mild to moderate in severity.
During the marketing of loratadine, alopecia, anaphylaxis and abnormal hepatic function have been reported rarely.
There have been rare post-marketing reports of mechanical upper gastrointestinal tract obstruction in patients taking Clarityn-D 24Hour Extended Release. In most of these cases, patients have had a history of difficulty in swallowing tablets or have had known upper gastrointestinal narrowing or abnormal esophageal peristalsis.
During the marketing of loratadine, alopecia, anaphylaxis and abnormal hepatic functions have been reported rarely.
Isolated cases of acute generalized exanthematous pustulosis (AGEP), a form of severe skin reaction have been reported post-market with pseudoephedrine-containing products.